SLC15A1 and colorectal carcinoma: Thus, our study improves our understanding of the epigenetic repression of PEPT1 promoters in CRC, we successfully applied this knowledge to design an epigenetic combination therapy sensitizing CRC to UBEN in vitro and in vivo.